ERAS-4001

ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor developed for the treatment of KRAS-mutant solid tumors. It is designed to inhibit both mutant (G12X) and wildtype KRAS with high selectivity, sparing HRAS and NRAS wildtype proteins. This selectivity may provide a superior therapeutic window compared to broader pan-RAS inhibitors by reducing off-target effects. ERAS-4001 demonstrates strong preclinical in vitro potency against multiple KRAS mutations as well as wildtype amplifications, potentially limiting resistance mechanisms mediated through wildtype activation. The compound shows activity against both GTP-bound (active) and GDP-bound (inactive) states of KRAS at single-digit nanomolar IC50s and has induced tumor regression in various preclinical models. It exhibits favorable absorption, distribution, metabolism, excretion (ADME), and pharmacokinetic properties in animal studies. The drug is currently being evaluated in the BOREALIS-1 Phase 1 clinical trial for patients with KRAS-mutant solid tumors[1][2][3][4][5][6][8].